Novo Nordisk's hemophilia drug shows potential as once-monthly treatment

New phase I and II data supports the firm’s continued work toward a phase III of Mim8, a hemophilia drug that could achieve blockbuster status, according to some estimates.

Novo Nordisk’s hemophilia drug, Mim8, has ”demonstrated potential as a once-monthly treatment” for hemophilia A, the company reported in a Monday press release.

Data from phase I and II studies, which was made public at a conference in London, confirm this potential.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs